Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$493.11M$493.11M−1.1% vs Q1 2020 Net Income$12.75M$12.75M−89.4% vs Q1 2020 EPS Diluted$0.04$0.04−94.9% vs Q1 2020 Gross Profit$191,562,000+4.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow$148,128,000+202.1% Free Cash Flowderived$136,352,000+227.3% Margins · derivedGross margin38.8%+2.0 pt vs Q1 2020
Operating margin9.3%−2.3 pt vs Q1 2020
Net margin2.6%−21.6 pt vs Q1 2020
ended Mar 31, 2021 · filed May 7, 2021 · 37 d after period end